These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31272550)

  • 1. Accelerated Allograft Vasculopathy With Rituximab After Cardiac Transplantation.
    Starling RC; Armstrong B; Bridges ND; Eisen H; Givertz MM; Kfoury AG; Kobashigawa J; Ikle D; Morrison Y; Pinney S; Stehlik J; Tripathi S; Sayegh MH; Chandraker A;
    J Am Coll Cardiol; 2019 Jul; 74(1):36-51. PubMed ID: 31272550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined heart and kidney transplantation-Is there a protective effect against cardiac allograft vasculopathy using intravascular ultrasound?
    Sato T; Cheng R; Azarbal B; Kittleson M; Patel J; Czer L; Levine R; Dimbil S; Olymbios M; Anzai T; Kransdorf E; Chang DH; Hamilton MA; Esmailian F; Kobashigawa J
    J Heart Lung Transplant; 2019 Sep; 38(9):956-962. PubMed ID: 31301966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients.
    Broch K; Lemström KB; Gustafsson F; Eiskjær H; Karason K; Gjesdal G; Fagerland MW; Pentikainen M; Lommi J; Gude E; Andreassen AK; Clemmensen TS; Christiansen EH; Bjørkelund E; Berg ES; Arora S; Gullestad L
    JACC Heart Fail; 2024 Oct; 12(10):1677-1688. PubMed ID: 38934968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.
    Arora S; Andreassen AK; Karason K; Gustafsson F; Eiskjær H; Bøtker HE; Rådegran G; Gude E; Ioanes D; Solbu D; Dellgren G; Ueland T; Aukrust P; Gullestad L;
    Circ Heart Fail; 2018 Sep; 11(9):e004050. PubMed ID: 30354362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of high-intensity interval training on progression of cardiac allograft vasculopathy.
    Nytrøen K; Rustad LA; Erikstad I; Aukrust P; Ueland T; Lekva T; Gude E; Wilhelmsen N; Hervold A; Aakhus S; Gullestad L; Arora S
    J Heart Lung Transplant; 2013 Nov; 32(11):1073-80. PubMed ID: 23906899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation.
    Tydén G; Genberg H; Tollemar J; Ekberg H; Persson NH; Tufveson G; Wadström J; Gäbel M; Mjörnstedt L
    Transplantation; 2009 May; 87(9):1325-9. PubMed ID: 19424032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation.
    Topilsky Y; Hasin T; Raichlin E; Boilson BA; Schirger JA; Pereira NL; Edwards BS; Clavell AL; Rodeheffer RJ; Frantz RP; Maltais S; Park SJ; Daly RC; Lerman A; Kushwaha SS
    Circulation; 2012 Feb; 125(5):708-20. PubMed ID: 22207715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.
    Arora S; Ueland T; Wennerblom B; Sigurdadottir V; Eiskjær H; Bøtker HE; Ekmehag B; Jansson K; Mortensen SA; Saunamaki K; Simonsen S; Gude E; Bendz B; Solbu D; Aukrust P; Gullestad L
    Transplantation; 2011 Jul; 92(2):235-43. PubMed ID: 21677600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optical coherence tomography for characterization of cardiac allograft vasculopathy in late survivors of pediatric heart transplantation.
    Tomai F; De Luca L; Petrolini A; Di Vito L; Ghini AS; Corvo P; De Persio G; Parisi F; Pongiglione G; Giulia Gagliardi M; Prati F
    J Heart Lung Transplant; 2016 Jan; 35(1):74-79. PubMed ID: 26452998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial ischemic-fibrotic injury after human heart transplantation is associated with increased progression of vasculopathy, decreased cellular rejection and poor long-term outcome.
    Yamani MH; Haji SA; Starling RC; Tuzcu EM; Ratliff NB; Cook DJ; Abdo A; Crowe T; Secic M; McCarthy P; Young JB
    J Am Coll Cardiol; 2002 Mar; 39(6):970-7. PubMed ID: 11897438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of donor and recipient gender on cardiac allograft vasculopathy. An intravascular ultrasound study.
    Mehra MR; Stapleton DD; Ventura HO; Escobar A; Cassidy CA; Smart FW; Collins TJ; Ramee SR; White CJ
    Circulation; 1994 Nov; 90(5 Pt 2):II78-82. PubMed ID: 7955289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte colony-stimulating factor therapy is associated with a reduced incidence of acute rejection episodes or allograft vasculopathy in heart transplant recipients.
    Vrtovec B; Haddad F; Pham M; Deuse T; Fearon WF; Schrepfer S; Leon S; Vu T; Valantine H; Hunt SA
    Transplant Proc; 2013; 45(6):2406-9. PubMed ID: 23953556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTor-inhibition within the first days after pediatric heart transplantation is a potentially safe option to prevent cardiac allograft vasculopathy.
    Kreienbaum H; Stiller B; Kubicki R; Bobrowski A; Kroll J; Fleck T
    Pediatr Transplant; 2024 Mar; 28(2):e14698. PubMed ID: 38433342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart transplant recipients: Design of the randomized controlled EVOLVD trial.
    Broch K; Gude E; Karason K; Dellgren G; Rådegran G; Gjesdal G; Gustafsson F; Eiskjaer H; Lommi J; Pentikäinen M; Lemström KB; Andreassen AK; Gullestad L
    Clin Transplant; 2020 Sep; 34(9):e13984. PubMed ID: 32445429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
    Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial.
    Kobashigawa JA; Pauly DF; Starling RC; Eisen H; Ross H; Wang SS; Cantin B; Hill JA; Lopez P; Dong G; Nicholls SJ;
    JACC Heart Fail; 2013 Oct; 1(5):389-99. PubMed ID: 24621971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients.
    Costanzo MR; Koch DM; Fisher SG; Heroux AL; Kao WG; Johnson MR
    J Heart Lung Transplant; 1997 Feb; 16(2):169-78. PubMed ID: 9059928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
    Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
    Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive model to assess risk for cardiac allograft vasculopathy: an intravascular ultrasound study.
    Mehra MR; Ventura HO; Chambers R; Collins TJ; Ramee SR; Kates MA; Smart FW; Stapleton DD
    J Am Coll Cardiol; 1995 Nov; 26(6):1537-44. PubMed ID: 7594082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.